- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06369766
REtinal Markers In Neuroinflammatory Diseases ("REMIND")
Retinal Markers in Neuroinflammatory Diseases: a Prospective Observational Study
Study Overview
Status
Conditions
Detailed Description
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) and represents one of the most common neurological disorders affecting young adults worldwide and often leads to significant disability over time. While MS typically presents with recurrent neurological symptoms known as relapses, most patients also experience progressive neurological deterioration independent of relapses, referred to as progression independent of relapse activity (PIRA). PIRA is a major contributor to long-term disability and represents a significant challenge in the management of MS. Early identification of patients at high risk to develop PIRA is crucial for therapeutic decisions and testing treatment efficacy, highlighting the urgent need for accurate predictive markers of progression in MS.
The primary objective of this longitudinal, observational, prospective, single center study is to investigate the predictive value of various retinal markers in predicting PIRA in MS patients.
The study assesses several easily obtained, non-invasive retinal measures:
- Neuroaxonal loss in the retina: This serves as a marker of neurodegeneration in the CNS. It will be assessed by measuring the volume of the ganglion cell-inner plexiform layer and the thickness of the peripapillary retinal nerve fiber layer using optical coherence tomography (OCT).
- Neuroinflammation in the retina: This will be assessed by evaluating thickening of other retinal layers in OCT, particularly the inner nuclear layer.
- Fixation instability of the patients: This serves as a marker of global neuronal dysfunction in the CNS. It will be measured using Scanner Laser Ophthalmoscopy-OCT.
- Structural changes of the retinal vessels: Particularly, the arteriolar and venular diameters will be assessed. This serves as a marker of systemic microvascular health and will be measured using static retinal vessel analysis.
- Functional/perfusional changes of the retinal vessels: For a subgroup of patients, this will be evaluated using OCT-angiography, and/or dynamic retinal vessel analysis, and/or laser speckle flowgraphy. These measures provide insights into the functional and perfusional changes of the retinal vessels.
As secondary objectives, this study comprises:
- Comparison with other biomarkers of neuroaxonal damage to determine whether the retinal markers are independent and/or stronger predictors of PIRA.
- Comparison with the retinal markers of Healthy Controls and patients with other neuroinflammatory diseases of the CNS to understand the differences in mechanisms of damage.
- Investigating the associations among the various retinal measures to understand the relationship between neuroaxonal loss, functional deficits and vascular changes in MS.
Data will be collected at baseline and annually over up to 5 years, or for some MS patients, up to 10 years, to evaluate changes in retinal markers and their correlation with disease progression. This comprehensive assessment will provide valuable insights into the utility of retinal markers in predicting PIRA and their relationship with disease severity and progression in MS.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Athina Papadopoulou, PD Dr. med.
- Phone Number: +41 61 32 85704
- Email: Athina.Papadopoulou@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- University Hospital Basel, Department of Neurology
-
Contact:
- Athina Papadopoulou, PD Dr. med.
- Phone Number: +41 61 32 85704
- Email: Athina.Papadopoulou@usb.ch
-
Principal Investigator:
- Athina Papadopoulou, PD Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
All groups:
- Age >18 years old
Patients with Multiple Sclerosis:
- Diagnosis of Multiple Sclerosis, according to the last revisions of the McDonald Criteria (2017)
Patients with other neuroinflammatory diseases:
- Diagnosis of Neuromyelitis optica spectrum disorder or Myelin oligodendrocyte glycoprotein antibody disease or other neuroinflammatory disorders other than Multiple Sclerosis
Exclusion Criteria:
All groups:
- Inability to undergo Optical Coherence Tomography (OCT) and/or retinal vessel imaging (e.g. severe nystagmus that prevents eye fixation on both eyes)
- Presence of any ocular pathology that may interfere with the validity of the OCT/retinal vessel analysis (cataracts, glaucoma, history of refractive defects >6 D etc.).
- Pregnancy and Lactation
Healthy Controls
- History of other neurological conditions: participants with a history of other significant neurological conditions that might interfere with the assessment or interpretation of the signs and symptoms will be excluded (e.g. confirmed Stroke, Acute disseminated encephalomyelitis, Chronic inflammatory Demyelinating Disease, Polyneuropathy, etc.)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with Multiple Sclerosis
|
OCT is used to measure:
The "scanner laser ophthalmoscopy"-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability. In a subgroup of participants, the "angiography"-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus. Static retinal vessel analyzer is used to determine:
In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations.
Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
|
Healthy Controls
Healthy control subjects without neurological diseases
|
OCT is used to measure:
The "scanner laser ophthalmoscopy"-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability. In a subgroup of participants, the "angiography"-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus. Static retinal vessel analyzer is used to determine:
In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations.
Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
|
Patients with other neuroinflammatory diseases of the CNS
|
OCT is used to measure:
The "scanner laser ophthalmoscopy"-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability. In a subgroup of participants, the "angiography"-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus. Static retinal vessel analyzer is used to determine:
In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations.
Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurence of Progression Independent of Relapse Activity (PIRA)
Time Frame: 5 Years (or for a subgroup up to 10 years) after baseline
|
The group of "Multiple Sclerosis patients" undergo a detailed neurological interview and examination for the calculation of the Expanded Disability Status Scale (EDSS) at each clinical visit every 6 or 12 months.
The EDSS worsening is used to define PIRA retrospectively (increase of ≥1.5 points if baseline EDSS was 0 points, increase of ≥1.0 points if baseline EDSS was 1-5.5 points or increase of ≥0.5 point if baseline EDSS was >5.5 points), with no relapse between the reference- event- and confirmation score visits.
Relapse is defined as objectively observed signs typical of an acute CNS inflammatory demyelinating event, with duration of at least 24hours in the absence of fever or infection, separated from the last relapse by ≥30 days.
The occurence of PIRA (yes/no) is assessed at the end of the follow-up period of the different retinal markers (5 years or for a subgroup up to 10 years after baseline).
|
5 Years (or for a subgroup up to 10 years) after baseline
|
Neuroaxonal loss in the retina (as marker of neurodegeneration in the CNS)
Time Frame: Baseline and once every year over up to 5 years
|
To determine the neuroaxonal loss in the retina, the thickness of the peripapillary retinal nerve fiber layer and the volume of the ganglion cell-inner plexiform layer are assessed by optical coherence tomography (OCT).
|
Baseline and once every year over up to 5 years
|
Neuroinflammation in the retina
Time Frame: Baseline and once every year over up to 5 years
|
To determine the neuroinflammation in the retina, the thickening of the outer plexiform layer, outer nerve layer and ,in particular, of the inner nuclear layer are assessed by OCT.
|
Baseline and once every year over up to 5 years
|
Fixation instability (as marker of global neuronal dysfunction in the CNS)
Time Frame: Baseline and once every year over up to 5 years
|
To determine the fixation instability, visual fixation measurements are recorded via the "Scanner Laser Ophthalmoscopy"-function of the OCT device (as described by Mallery et al., 2018; PMID: 29340646).
|
Baseline and once every year over up to 5 years
|
Structural changes of the retinal vessels (as marker of systemic microvascular health)
Time Frame: Baseline and once every year over up to 5 years
|
To determine structural changes of the retinal vessels, the retinal arterior and venular diameters are measured by static retinal vessel analysis.
|
Baseline and once every year over up to 5 years
|
(For a subgroup of participants) Functional/perfusional changes of the retinal vessels
Time Frame: Baseline and once every year over up to 5 years
|
To determine the functional/perfusional changes of the retinal vessels, a subgroup of participants (patients= 100, Healthy Controls= 50) undergoes additional examinations:
|
Baseline and once every year over up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative value of retinal markers for the prediction of PIRA compared to or combined with other biomarkers of neuroaxonal damage
Time Frame: Baseline and once every year over up to 5 years
|
Data regarding other biomarkers (serum neurofilament light chain and brain volume on magnet resonance imaging) that are already available within the clinical routine and/or the SMSC study are used to assess the relative value of the retinal markers described above under primary outcome measures 2-6 in predicting PIRA, both independently or in combination with these other biomarkers.
|
Baseline and once every year over up to 5 years
|
Comparison of the examined retinal markers of Multiple Sclerosis patients with Healthy Controls and with patients with other neuroinflammatory diseases of the CNS
Time Frame: Baseline and once every year over up to 5 years
|
Examined retinal markers are compared between the different groups to understand the relationship among the different measures independently of disease.
|
Baseline and once every year over up to 5 years
|
The relationship between neuroaxonal loss, functional deficits and vascular changes in Multiple Sclerosis
Time Frame: Baseline and once every year over up to 5 years
|
Investigation of the associations among the examined retinal measures to understand the relationship between neuroaxonal loss, functional deficits and vascular changes in Multiple Sclerosis.
|
Baseline and once every year over up to 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Athina Papadopoulou, PD Dr. med., University Hospital Basel, Department of Neurology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-02144; ko23Papadopoulou4
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Optical coherence tomography (OCT)
-
China National Center for Cardiovascular DiseasesBeijing Tongren HospitalNot yet recruiting
-
University of PalermoRecruitingOral Disease | Oral Cancer | Actinic Keratoses | Oral Leukoplakia | Oral Squamous Cell Carcinoma | Oral Lichen Planus | Graft-versus-host-disease | Proliferative Verrucous Leukoplakia | Actinic Cheilitis | Oral Potentially Malignant Disorder | Oral Erythroplakia | Oral Lichenoid LesionItaly
-
Assiut UniversityNot yet recruitingMigraine Without Aura | Migraine With Aura
-
Xuzhou Third People's HospitalShandong Jiwei Medical Products Co., LtdRecruitingNon ST Segment Elevation Myocardial Infarction | Unstable AnginasChina
-
Diagram B.V.Isala; St. Jude Medical Nederland B.V.CompletedCoronary Artery Disease | Diabetes Mellitus | Coronary AtherosclerosesNetherlands
-
Sohag UniversityNot yet recruiting
-
Vanderbilt University Medical CenterNot yet recruitingCorneal TransplantationUnited States
-
Assiut UniversityNot yet recruitingNeurodegeneration | Retinal Neuropathy
-
University of Wisconsin, MadisonRecruitingVascular StainsUnited States